Published in Lancet Oncol on July 16, 2013
Study of Denosumab in Subjects With Giant Cell Tumor of Bone | NCT00680992
Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab (2014) 2.17
Rapid skeletal turnover in a radiographic mimic of osteopetrosis. J Bone Miner Res (2014) 2.00
The clinical approach toward giant cell tumor of bone. Oncologist (2014) 1.46
Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol (2015) 1.14
Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial. Ann Oncol (2015) 1.14
Benign tumours of the bone: A review. J Bone Oncol (2015) 1.02
Severe hypercalcemia following denosumab treatment in a juvenile patient. J Bone Miner Metab (2015) 0.93
Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy. Skeletal Radiol (2015) 0.92
A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab. Clin Orthop Relat Res (2015) 0.90
Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab. Gastroenterol Rep (Oxf) (2014) 0.88
Giant cell tumour of bone: new treatments in development. Clin Transl Oncol (2015) 0.87
Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol (2015) 0.87
An eggshell-like mineralized recurrent lesion in the popliteal region after treatment of giant cell tumor of the bone with denosumab. Skeletal Radiol (2014) 0.86
Two years' experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis (2014) 0.86
Pain and fracture after anterior cruciate ligament reconstruction caused by giant cell tumour of the distal femur. BMJ Case Rep (2013) 0.84
Surgical treatment for pelvic giant cell tumor: a multi-center study. World J Surg Oncol (2016) 0.84
Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clin Sarcoma Res (2016) 0.82
RANK and RANK ligand expression in primary human osteosarcoma. J Bone Oncol (2015) 0.82
Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series. World J Surg Oncol (2016) 0.82
Denosumab treatment of giant cell tumour of bone. Lancet Oncol (2013) 0.81
Giant-cell tumor of bone: treatment options and role of denosumab. Biologics (2015) 0.81
Rapidly growing giant cell tumor of bone in a skeletally immature girl. Skeletal Radiol (2015) 0.80
Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report. Acta Orthop (2015) 0.80
Therapeutic radiotherapy for giant cell tumor of the spine: a systemic review. Eur Spine J (2015) 0.80
Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab. Case Rep Med (2015) 0.80
Neurological Recovery in Two Patients with Cauda Equina Syndrome Secondary to L5 Lumbar Spine Giant Cell Tumour after Treatment with Denosumab without Surgery. Asian Spine J (2016) 0.79
Giant cell tumors of the sacrum--a nationwide study on midterm results in 26 patients after intralesional excision. Eur Spine J (2014) 0.79
Giant cell tumor of bone in a patient with diagnosis of primary hyperparathyroidism: a challenge in differential diagnosis with brown tumor. Skeletal Radiol (2013) 0.79
Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review. Med Oral Patol Oral Cir Bucal (2016) 0.79
Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor. Asian Spine J (2016) 0.78
Enrichment of c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib. Cell Death Dis (2014) 0.78
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology (2015) 0.77
Giant Cell Tumor of the Larynx Treated by Surgery and Adjuvant Denosumab: Case Report and Review of the Literature. Head Neck Pathol (2015) 0.76
The dilemma of denosumab: Salvage of a femoral head giant cell tumour. Int J Surg Case Rep (2014) 0.76
Microenvironmental Targets in Sarcoma. Front Oncol (2015) 0.76
Giant cell tumors of the clivus: Case report and literature review. Surg Neurol Int (2015) 0.75
Advances in sarcoma diagnostics and treatment. Oncotarget (2016) 0.75
Commentary on: "L4 and L5 Spondylectomy for En Bloc Resection of Giant Cell Tumor and Review of the Literature". Evid Based Spine Care J (2014) 0.75
UK guidelines for the management of bone sarcomas. Clin Sarcoma Res (2016) 0.75
From Bench to Bedside: Targeted Therapy, Denosumab, and 21st Century Orthopaedics: Targets Abound, But Where Are The Therapies? Clin Orthop Relat Res (2016) 0.75
Denosumab treatment for progressive skull base giant cell tumor of bone in a 14 year old female - a case report and literature review. Ital J Pediatr (2017) 0.75
Rank ligand as a target in musculoskeletal neoplasms. Curr Rev Musculoskelet Med (2015) 0.75
Bone resorption: an actor of dental and periodontal development? Front Physiol (2015) 0.75
Conservative surgery in the treatment of giant cell tumor of the sacrum: 35 years' experience. J Neurosurg Spine (2015) 0.75
A case of thoracic giant cell tumor of bone and discussion of radiological features and current management practices. Radiol Case Rep (2016) 0.75
Denosumab treatment of inoperable or locally advanced giant cell tumor of bone. Oncol Lett (2016) 0.75
Multidisciplinary Approach to Management of Temporal Bone Giant Cell Tumor. J Neurol Surg Rep (2016) 0.75
RANK-RANKL signalling in cancer. Biosci Rep (2016) 0.75
Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives. J Clin Med (2014) 0.75
Successful Intravascular Correction of Intratumoral Pseudoaneurysm by Erosion of the Aorta in a Patient with Thoracic Giant Cell Tumor of Bone Responding to Denosumab. Case Rep Oncol Med (2015) 0.75
Clinical characteristics and prognoses of six patients with multicentric giant cell tumor of the bone. Oncotarget (2016) 0.75
Remarkable regression of a giant cell tumor of the cervical spine treated conservatively with denosumab: A case report. Int J Surg Case Rep (2016) 0.75
Histological Regression of Giant Cell Tumor of Bone Following RANK Ligand Inhibition. J Investig Med High Impact Case Rep (2014) 0.75
Successful treatment with denosumab in a patient with sacral giant cell tumor of bone refractory to combination therapy with arterial embolization and zoledronic acid: A case report. Mol Clin Oncol (2017) 0.75
Surgical Outcomes in Patients with High Spinal Instability Neoplasm Score Secondary to Spinal Giant Cell Tumors. Global Spine J (2015) 0.75
Use of denosumab in recurrent chondroblastoma of the squamous temporal bone: a case report. Clin Case Rep (2017) 0.75
Denosumab: an Emerging Therapy in Pediatric Bone Disorders. Curr Osteoporos Rep (2017) 0.75
Diagnosis and treatment of Paget's disease of bone : A clinical practice guideline. Wien Med Wochenschr (2016) 0.75
Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). Cancer Chemother Pharmacol (2017) 0.75
TRAIL-R1 as a novel surface marker for circulating giant cell tumor of bone. Oncotarget (2017) 0.75
How safe and effective is denosumab for bone giant cell tumour? Int Orthop (2017) 0.75
Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy. Eur Spine J (2017) 0.75
Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery. Skeletal Radiol (2017) 0.75
Giant cell tumor of bone revisited. SICOT J (2017) 0.75
Multiple giant cell tumors of bone arising from multiple fatty tumors. Skeletal Radiol (2016) 0.75
Cyberknife stereotactic radiosurgery and denosumab for giant cell tumour of the skull base: Case report. Rep Pract Oncol Radiother (2017) 0.75
Total en bloc spondylectomy of the eleventh thoracic vertebra following denosumab therapy for the treatment of a giant cell tumor. Oncol Lett (2017) 0.75
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 11.37
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell (2007) 10.13
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol (2010) 6.47
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet (2008) 5.63
Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol (2007) 5.50
Cachexia: a new definition. Clin Nutr (2008) 5.49
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA (2012) 5.00
Further Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan: Response. Radiology (2017) 4.99
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006) 4.92
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med (2015) 4.78
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol (2011) 4.19
Exercise program for nursing home residents with Alzheimer's disease: a 1-year randomized, controlled trial. J Am Geriatr Soc (2007) 4.05
Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol (2003) 3.93
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol (2009) 3.72
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol (2007) 3.38
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol (2012) 3.35
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31
Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med (2006) 3.11
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res (2006) 3.00
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer (2008) 2.91
Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet (2007) 2.91
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer (2011) 2.85
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst (2007) 2.85
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol (2008) 2.85
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol (2010) 2.74
Assessing the multimodal management of advanced solitary fibrous tumors of the pleura in a routine practice setting. J Thorac Oncol (2015) 2.68
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol (2010) 2.66
Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol (2010) 2.66
Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med (2010) 2.62
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol (2011) 2.62
Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol (2011) 2.60
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer (2005) 2.54
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res (2009) 2.51
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol (2011) 2.46
Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res (2012) 2.46
Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol (2003) 2.44
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest (2004) 2.40
The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A (2009) 2.38
Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res (2004) 2.34
Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev (2004) 2.20
Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol (2005) 2.15
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol (2012) 2.15
Gas sensor array based on metal-decorated carbon nanotubes. J Phys Chem B (2006) 2.14
Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One (2011) 2.13
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. J Clin Oncol (2004) 2.05
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ (2012) 2.04
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol (2012) 2.02
Mean arterial pressure required for maintaining patency of extracranial-to-intracranial bypass grafts: an investigation with computational hemodynamic models-case series. Neurosurgery (2012) 2.02
Acute lower respiratory tract infections in children: possible criteria for selection of patients for antibiotic therapy and hospital admission. 1984. Bull World Health Organ (2003) 1.99
Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol (2003) 1.99
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol (2011) 1.95
A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. Cell Host Microbe (2013) 1.95
Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol (2005) 1.94
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol (2012) 1.84
Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.82
Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol (2003) 1.78
Policies, Political-Economy, and Swidden in Southeast Asia. Hum Ecol Interdiscip J (2009) 1.74
Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol (2011) 1.73
Clinical considerations for the development of biosimilars in oncology. MAbs (2015) 1.71
Desmoplastic small round cell tumor: current management and recent findings. Sarcoma (2012) 1.68
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer (2006) 1.65
High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer (2004) 1.65
Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol (2011) 1.64
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res (2009) 1.64
Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol (2006) 1.62
International study on low-grade primary central nervous system lymphoma. Ann Neurol (2006) 1.59
Evaluation of ocular surface disorders: a new diagnostic tool based on impression cytology and confocal laser scanning microscopy. Br J Ophthalmol (2009) 1.59
Overexpression, purification, and characterization of recombinant Ca-ATPase regulators for high-resolution solution and solid-state NMR studies. Protein Expr Purif (2003) 1.58
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 1.58
Gastrointestinal stromal tumors: biology and treatment. Oncology (2003) 1.57
T cell activation results in conformational changes in the Src family kinase Lck to induce its activation. Sci Signal (2013) 1.56
Long-term effectiveness of autologous cultured limbal stem cell grafts in patients with limbal stem cell deficiency due to chemical burns. Clin Experiment Ophthalmol (2011) 1.56
Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest (2007) 1.56
Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer (2010) 1.54
Continuous venovenous hemofiltration with or without extracorporeal membrane oxygenation in children. Pediatr Crit Care Med (2007) 1.54